leadf
logo-loader
viewFaron Pharmaceuticals Oy
(
AIM:FARNOTC:FPHAF
)

Faron Pharma raises €15mln to 'expand and accelerate' work in the clinic

The European Investment Council Fund was the largest new investor

Faron Pharmaceuticals Ltd -

Faron Pharma PLC (LON:FARN) has raised €15mln from an accelerated share placing that will be used to fund its work in the clinic.

New shares were priced at €4.26 each, a 5% discount to the 30-day average.

The European Investment Council (EIC) Fund was the largest new shareholder, and Faron is the first publicly-listed company the EIC Fund has invested in.

Chief executive, Dr Markku Jalkanen, said: "We are delighted to have received this significant support from our existing and new investors in this successful financial round.

“In particular we would like to welcome the European Innovation Council Fund, a breakthrough initiative from the European Commission.”

The proceeds from the placing will be used to 'accelerate and expand' work on Bexmarilimab, Faron’s experimental cancer treatment.

This will include testing higher frequency of dosing. It also plans three new trials to run alongside the ongoing MATINS study.

Cash will be put to work developing Traumakine, Faron’s drug for acute respiratory distress.

Researchers are readying to launch a phase II/III clinical assessment in the US, while preparations are also being made for an additional clinical indication for the treatment.

Quick facts: Faron Pharmaceuticals Oy

Follow
AIM:FARN

Price: 390 GBX

Market Cap: £196.79 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Faron Pharmaceuticals presenting at the Proactive One2One Virtual Forum -...

Faron is a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system in order to tackle cancer and inflammation. Since our founding in 2007, our goal has been to develop a diverse and unique pipeline rooted in high...

3 days, 22 hours ago

2 min read